Acer Therapeutics Inc

Acer Therapeutics — Investor Presentation (January 2021)

45 slides from Acer Therapeutics's investor presentation, Jan 15, 2021

  1. Slide 1: Corporate Presentation January 15, 2021

    Developing Therapeutics for the Treatment of Serious Rare and Life-Threatening Diseases with Significant Unmet Medical Needs Corporate Presentation January 15, 2021 Nasdaq: ACER Exhibit 99.1

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in

  3. Slide 3: Corporate Overview

    Corporate Overview Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious rare and life-threatening diseases with significant unmet medical needs Headquartered: Newton, MA Headcount: 20 Founded: December 2013 Public: September 2017 Cash

  4. Slide 4: Leadership Team

    Leadership Team Chris Schelling CEO & Founder 21 years; strategic commercial development & orphan BiIOMAR IN Harry Paimin my 26+ years; corporate ie triande experience Novelos Chief Operating & Financial Officer ee Se ofncer 2 years; sales, market access & product launch * Biogen ohn Gepey ottcer 18

  5. Slide 5: Investment Highlights

    Investment Highlights Acer’s pipeline includes four programs: ACER-001 (a taste-masked, immediate release formulation of sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD) EDSIVO™ (celiprolol) fo

  6. Slide 6: Clinical Pipeline

    6 Clinical Pipeline ACER * Requires bioequivalence (BE) trial under fed conditions ** Additional capital resources required to fund these programs going forward *** Response received March 2020 denying appeal of the Complete Response Letter but describing possible paths forward for Acer to explore t

  7. Slide 7: ACER-001: taste-masked immediate release sodium phenylbutyrate

    Small molecule with unique MOAs in various disorders UCDs: NaPB is a prodrug of phenylacetate, a NH4+ scavenger MSUD: NaPB is an allosteric inhibitor of BCKD kinase UCDs: A group of metabolic genetic diseases that lead to toxic build-up of NH4+ UCDs: Currently treated with Ravicti®, Buphenyl®, Ammon

  8. Slide 8: ACER-001 Urea Cycle Disorders

    Newborns with severe urea cycle disorders become significantly ill with symptoms that mimic sepsis -- failure to feed, lethargy, respiratory distress, seizures and ultimately coma Children and adults with milder (or partial) urea cycle enzyme deficiencies may go years without a diagnosis, until a tr

  9. Slide 9: ACER-001 Mechanism of Action

    9 Berry S, et al. Molecular Genetics and Metabolism 125 (2018) 251–257. ACER-001 Mechanism of Action Nitrogen scavenger therapy Alternative pathway treatment diverts nitrogen from the urea cycle to alternate routes of excretion Both Ravicti® and Buphenyl® metabolize to phenylbutyrate (PBA), a prodru

  10. Slide 10: ACER-001 Unmet Need

    10 ACER-001 Unmet Need Buphenyl®: Foul odor and foul/bitter taste; considered unpalatable1 64% of patients reported it is difficult to take because of taste Physicians reported that 25-33% of patients took less than target dose due to tolerability Only 25% of patients indicated that they never miss

  11. Slide 11: ACER-001 Development Overview: Regulatory Path 505(b)(2)

    Regulatory Path: 505(B)(2)  RLD: Buphenyl® Bridging Studies: two (2) studies Fasted (pre-meal) study: lifecycle opportunity [completed] Fed study: pivotal – will be on label at launch [completion Q1’21] Taste Assessment Studies: two (2) studies At 5 and 10-minutes [completed] At 0 through 5-minutes

  12. Slide 12: ACER-001 Food Effect

    12 ACER-001 Food Effect * Based on data comparison of ACER-001 under fed conditions vs. published data of NaPB under fed conditions 1 ACER-001 Pivotal BE/BA Study (Part B) in healthy volunteers 2 Sci Rep 9, 17075 (2019). https://doi.org/10.1038/s41598-019-53628-x Maximum concentration (Cmax) ~2x hig

  13. Slide 13: ACER-001 Food Effect: In Silico Model

    13 ACER-001 Food Effect: In Silico Model Adult Virtual Patient Child Virtual Patient PAA (Safety1,2,3) uPAGN (Efficacy) 1 Mol Genet Metab. 2013 Dec; 110(4): 446-453. 2 Pediatr Res. 1986 Nov; 20(11):1117-21. 3 Cancer. 1995 Jun 15; 75(12):2932-8. ACER-001 in a fasted state required ~30% less PBA to ac

  14. Slide 14: ACER-001 Food Effect: Summary

    Dosing and Administration for Buphenyl®, Ravicti® and Pheburane® are all instructed to be given with food There is a significant food effect with NaPB The pharmacokinetic (PK) and pharmacodynamic (PD) properties of Ravicti® are indistinguishable in the fed or fasted states1 Dosing in a pre-meal sett

  15. Slide 15: ACER-001 Product Differentiation

    15 * Subject to FDA approval ** Molecular Genetics & Metabolism Reports 8 (2016) 43-47. *** Ravicti® and Buphenyl® pppy is based on patient weight and WAC price ACER-001 Product Differentiation

  16. Slide 16: ACER-001 Clinical & Regulatory Paths

    BE trial under fasted conditions successfully completed in Q1 2020 Received FDA Type C meeting feedback in August 2020 BE trial under fed conditions: Fully enrolled in December 2020 Anticipate completion in Q1 2021 Targeting pre-NDA meeting with FDA in Q2 2021 505(b)(2) NDA for UCDs: anticipate subm

  17. Slide 17: ACER-001 Value Proposition

    ACER-001 Value Proposition: Taste-masked formulation improves palatability & tolerability vs Buphenyl® Bioequivalence to Buphenyl® in fed dosing currently being investigated (assuming positive data from fed BE study) New fasted (pre-meal) dosing data suggests ability to optimize Rx dosing approach2

  18. Slide 18: ACER-001 IP / Exclusivities

    18 ACER-001 IP / Exclusivities IP: Filed formulation composition of matter patent application (priority date Oct. 2016) Issued patents (US/EP): “Methods of modulation of branched chain acids and uses thereof” [US PATENT NO. 10,092,532], licensed from Baylor College of Medicine relating to MSUD In ad

  19. Slide 19: EDSIVO Mechanism of Action and Disease Overview

    EDSIVO™ has a unique pharmacological profile β2 and β3 adrenergic receptor agonist; selective β1 and ⍺2 adrenergic receptor antagonist; activates endothelial Nitric Oxide Synthase (eNOS) EDSIVO’s™ potential beneficial effects in vEDS thought to be through vascular dilatation and smooth muscle relaxa

  20. Slide 20: EDSIVO Vascular Ehlers-Danlos Syndrome (vEDS)

    Ehlers-Danlos syndrome (EDS) is a group of hereditary disorders of connective tissue vEDS (EDS type IV) is the severe subtype: Characterized by aneurysms, dissections and/or ruptures Vascular Hollow Organs (e.g. gastrointestinal, uterine) Autosomal dominant (50%); spontaneous mutations (50%) Diagnos

  21. Slide 21: EDSIVO Mechanism of Action

    Cardiology in Review 2017;25: 247–253. * Hypertension 2003 Nov;42(5):1004-13. EDSIVO™ has a unique pharmacological profile: β2 and β3 adrenergic receptor agonist Selective β1 and ⍺2 adrenergic receptor antagonist Intrinsic sympathomimetic activity (ISA+) Lacks non-specific membrane effects Activates

  22. Slide 22: EDSIVO BBEST Trial: COL3A1+ Subpopulation

    Efficacy: 76% reduction in the risk of fatal or nonfatal cardiac or arterial events in COL3A1+ EDSIVO™ patients vs. control group over mean follow-up of 47 months 75% reduction in risk of primary (cardiac or arterial events) and secondary (intestinal or uterine rupture) events in COL3A1+ EDSIVO™ pat

  23. Slide 23: EDSIVO FDA CRL and Next Steps

    June 2019: Received CRL from FDA CRL stated it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS December 2019: Submitted Formal Dispute Resolution Request (FDRR) to the Office of New Drugs (ON

  24. Slide 24: EDSIVO Substantial Evidence of Effectiveness

    EDSIVO™ Substantial Evidence of Effectiveness Two adequate and well-controlled clinical investigations2 One adequate and well-controlled investigation plus confirmatory evidence2 One adequate and well-controlled investigation1 THE QUANTITY OF CLINICAL EVIDENCE TO ESTABLISH EFFECTIVENESS In many situ

  25. Slide 25: Osanetant: NK3 receptor antagonist

    Osanetant is a selective, non-peptide tachykinin NK3 receptor antagonist NK3R is the main receptor for neurokinin B (NKB), a tachykinin peptide primarily found in the arcuate nucleus (ARC) of the hypothalamus and KNDy neurons NK3R antagonism is an alternative to hormone replacement therapy for the t

  26. Slide 26: Osanetant History

    Acer acquired worldwide rights to osanetant from Sanofi in December 2018 Osanetant (SR142801) was the first selective non-peptide tachykinin NK3 receptor antagonist evaluated as a potential treatment for schizophrenia Clinical and laboratory safety results are available from 23 completed Phase 1 and

  27. Slide 27: Osanetant Vasomotor Symptoms (VMS)

    VMS, typically comprised of hot flashes and night sweats, are associated with decreases in reproductive hormones commonly associated with menopause (e.g. MR-VMS) 27 Osanetant Vasomotor Symptoms (VMS) The Oncologist, Oct 2003, vol.8 no.5 474-487. http://www.everydayhealth.com/menopause/science-behind

  28. Slide 28: Osanetant Induced Vasomotor Symptoms (iVMS)

    28 Osanetant Induced Vasomotor Symptoms (iVMS) Women with HR+ Breast Cancer (CaB) receiving Tamoxifen 84% of women experienced hot flashes1 80% experienced night sweats 60% experienced severe symptoms Symptoms persisted throughout 5 years of treatment and were mainly attributed to tamoxifen After 4.

  29. Slide 29: Osanetant Mechanism of Action

    Neurokinin B (NKB) belongs to a group of neuropeptides, called tachykinins or neurokinins, that includes substance-P (SP), neurokinin A (NKA), and two N-terminally extended forms of NKA, neuropeptide g and neuropeptide K The biological effects of tachykinins are mediated through specific receptors d

  30. Slide 30: Osanetant Clinical POC in VMS: Fezolinetant

    30 Osanetant Clinical POC in VMS: NK3R Antagonist Herman Depypere et al., ENDO2017. Fezolinetant is a NK3R antagonist being developed by Astellas for moderate-to-severe VMS At Week 4: fezolinetant group: 14/40 patients have ZERO hot flash placebo group: 2/40 patients have ZERO hot flash Average Dail

  31. Slide 31: Osanetant Clinical POC in VMS: Pavinetant

    31 Osanetant Clinical POC in VMS: NK3R Antagonist Prague J., et al. Menopause. 2018 Aug;25(8):862-869. Pavinetant (MLE4901) was a NK3R antagonist that was discontinued by Millendo for the treatment of polycystic ovary syndrome and menopausal hot flushes % change from baseline Hot flash frequency Hot

  32. Slide 32: Osanetant Development Plan

    Acer is partnering with leading universities to design & conduct clinical trials to evaluate osanetant in various patient populations with iVMS These include patients with medically or surgically iVMS (may include any/all of the following): Women who are BRCA+ and have had a PBSO Men with HR+ Prosta

  33. Slide 33: Emetine: Host-directed Therapy

    Host-directed Therapy Restores cellular stress response by interrupting the viral-induced MDM2-P53 loop, by shepherding RPS14 from cytosol into the nucleus, thus inhibiting viral replication Few drugs in development that are host-directed; believed to be only drug exploiting this particular MOA Mech

  34. Slide 34: Emetine background and history

    Emetine is one of the main alkaloids found in ipecacuanha (ipecac) root Clinically, emetine hydrochloride was originally marketed in the U.S. as a topical anti-infective in dental applications (ca 1890s by Eli Lilly and Company) Later, emetine hydrochloride for injection gained market adoption as a

  35. Slide 35: Emetine Mechanism of Action

    35 Emetine Mechanism of Action In high-density infected cells (A) emetine induces (1) nuclear translocation of RPS14 (2) followed by RPS14 binding to MDM2 (3 & 4) resulting in disruption of the interaction between MDM2-p53 (6) and MDM2- viral IE2 (5 & 7), and by RPS14 ubiquitination and degradation

  36. Slide 36: Emetine In Vitro Data

    36 Emetine In Vitro Data EC50 = concentration of a drug that gives half-maximal response. IC50 = concentration of an inhibitor where the response is reduced by half. CC50 = 50% cytotoxic concentration *EC50 / CC50 values = μM (unless otherwise noted) **For reference, the EC50 of remdesivir is 23.15

  37. Slide 37: Emetine In Vivo Efficacy Data

    37 Emetine In Vivo Efficacy Data Zika virus1 Ebola virus1 Cytomegalovirus2 Emetine suppresses ZIKV virus load in vivo. a Three-month-old SJL male mice were infected retro-orbitally with ZIKVBR followed by IP administration of emetine (1 mg/kg/day) for the next 6 days (N = 4 mice per group). Two grou

  38. Slide 38: Emetine PK & Tox Data

    38 Emetine PK & Tox Data Non-clinical pharmacokinetic studies show that emetine rapidly concentrates in the tissues, reaching levels that are 1,000- to 3,000-fold greater than in the plasma Emetine has been detected in a variety of tissues, including the heart, liver, lungs, intestines, kidney, sple

  39. Slide 39: Emetine Clinical Safety

    Patients with solid tumors treated with 1 mg/kg/day emetine daily via SC injection for 10 days (cumulative dose 650 mg) did not experience any notable toxicity1 Electrocardiographic abnormalities were observed, but not often associated with significant cardiac symptoms2,3,4 T wave inversion (TWI) is

  40. Slide 40: ACER Financial Overview

    40 Cash $6.2M as of September 30, 2020, combined with additional $5.4M of net proceeds subsequently received from ATM stock sales and Lincoln Park stock purchase agreement as of January 15, 2021 Expected to have sufficient capital to fund current operations into Q2 2021 Capitalization as of January

  41. Slide 41: Summary

    Summary 41 ACER * Assuming successful outcomes of BE trial under fed conditions, additional nonclinical work and long-term stability data ** Subject to successful IND submission and clearance $ Subject to additional capital Acer’s pipeline includes four programs: ACER-001 (a taste-masked, immediate

  42. Slide 42: Reference Slides

    Reference Slides 42

  43. Slide 43: MSUD disease overview

    MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC) ~800 patients in U.S., ~3,000 patients worldwide MSUD Family Support Group has >500 patients Part of

  44. Slide 44: ACER-001 MSUD: Clinical POC

    44 ACER-001 MSUD: Clinical POC Study Design: Open label pilot study1 at Baylor College of Medicine – 3 healthy and 5 MSUD subjects with late onset disease 3 days of steady-state protein diet*; then 3 days of NaPB + diet* BCAAs and BCKAs determined at day 3 of each study period (4 time points) Result

  45. Slide 45: MSUD: Market Opportunity

    About 1,000 MSUD patients in the U.S., ~3,000 WW* 20-25% MSUD patients in U.S. are Mennonite; incidence up to 1/380 Ashkenazi Jewish population; incidence of 1/26,000 No treatments currently approved for MSUD Early treatment may help reduce the rate of neuropsychological comorbidities and optimize g

Acer Therapeutics — Investor Presentation (January 2021) on 6ix